ISCT selects Elsevier to publish Cytotherapy

Published on January 8, 2013 at 11:44 PM · No Comments

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.

"Elsevier presented ISCT with unsurpassed reach into the global medical community, top class publishing services, and significant experience in this field. We are extremely confident that our collaboration with Elsevier will not only help Cytotherapy grow for the benefit of our members and readers, but also for the benefit of all scientists, technologists, regulators, manufacturing experts and others dedicated to translational development of safe and effective cell therapies," said ISCT President, Kurt Gunter, MD, FASCP.

Cytotherapy is a highly influential publication in the mainstream of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of these disciplines. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved in cell processing and therapy.

Senior Editor of Cytotherapy, John Barrett, MD, commented, "What matters is ensuring that new peer-reviewed treatments, developments, and studies reach as many specialists working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled opportunity to help the journal achieve this goal."

Glen Campbell, Executive Vice President at Elsevier added, "Cytotherapy is an established and reputable journal and we are honored that the International Society for Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure that this prestigious title develops further as the leading global forum and resource for developing and supporting innovative cellular therapies."

Source:

Posted in: Medical Procedure News | Medical Condition News | Healthcare News

Tags: , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma